{
    "title": "Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer",
    "abstract": "Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer Kalnisha Naidoo Patty T. Wai Sarah L. Maguire Frances Daley Syed Haider Divya Kriplani James Campbell Hasan Mirza Anita Grigoriadis Andrew Tutt Paul M. Moseley Tarek M.A. Abdel-Fatah Stephen Y. Chan Srinivasan Madhusudan Emad A. Rhaka Ian O. Ellis Christopher J. Lord Yinyin Yuan Andrew R. Green Rachael Natrajan",
    "authors": [
        "Kalnisha Naidoo",
        "Patty T. Wai",
        "Sarah L. Maguire",
        "Frances Daley",
        "Syed Haider",
        "Divya Kriplani",
        "James Campbell",
        "Hasan Mirza",
        "Anita Grigoriadis",
        "Andrew Tutt",
        "Paul M. Moseley",
        "Tarek M.A. Abdel-Fatah",
        "Stephen Y. Chan",
        "Srinivasan Madhusudan",
        "Emad A. Rhaka",
        "Ian O. Ellis",
        "Christopher J. Lord",
        "Yinyin Yuan",
        "Andrew R. Green",
        "Rachael Natrajan"
    ],
    "published_year": "Not available",
    "description": "",
    "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284786/",
    "doi": "https://doi.org/10.1158/1535-7163.MCT-17-0760",
    "citation_count": 31,
    "references": {
        "10983964": "CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality",
        "10951204": "CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer",
        "10800294": " ERBB2\u2010amplified lobular breast carcinoma exhibits concomitant CDK12 co\u2010amplification associated with poor prognostic features",
        "10122606": "Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms",
        "9617877": "CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma",
        "9557284": "Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels",
        "9496798": "Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery",
        "9455597": "PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies",
        "9328802": "Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment",
        "9254246": "MiR-155 deficiency protects renal tubular epithelial cells from telomeric and genomic DNA damage in cisplatin-induced acute kidney injury",
        "9098894": "CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer",
        "9052533": "Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status",
        "9010455": "Breast cancer in the era of integrating \u201cOmics\u201d approaches",
        "8230762": "Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?",
        "8210036": "CDK12: cellular functions and therapeutic potential of versatile player in cancer",
        "8167670": "CDK inhibitors in cancer therapy, an overview of recent development",
        "8015234": "Synthetic Lethality through the Lens of Medicinal Chemistry",
        "7998717": "Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development\u2013Review",
        "7847957": "Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers",
        "7812009": "TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis",
        "7734002": " CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression",
        "7663807": "Targeting DNA Damage Response in Prostate and Breast Cancer",
        "7349380": "CDK12: A Potent Target and Biomarker for Human Cancer Therapy",
        "7231148": "Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status",
        "7191097": "CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer",
        "7139603": "The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer",
        "6776914": " CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1\u2010ErbB\u2010PI3K signaling",
        "6743279": "Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression",
        "6602565": "Therapeutic targeting of transcriptional cyclin-dependent kinases",
        "6242340": "CDK12: An emerging therapeutic target for cancer",
        "6176317": "The Ethnic-Specific Spectrum of Germline Nucleotide Variants in DNA Damage Response and Repair Genes in Hereditary Breast and Ovarian Cancer Patients of Tatar Descent"
    },
    "journal": "Molecular cancer therapeutics",
    "topics": [
        "cancer, novel, biomarker",
        "evaluation, targeted, potential, expression",
        "dna, damage, novel, biomarker"
    ]
}